Professor Diana Gorog

Medicine & Life Sciences

1. Fibrinolysis 100%
2. Thrombosis 99%
3. Acute Coronary Syndrome 78%
4. Percutaneous Coronary Intervention 67%
5. ST Elevation Myocardial Infarction 64%
6. Atrial Fibrillation 54%
7. Blood Platelets 53%
8. Myocardial Infarction 49%
9. Hemorrhage 44%
10. Ticagrelor 37%
11. Anticoagulants 35%
12. Platelet Function Tests 31%
13. Therapeutics 27%
14. Coronary Artery Disease 23%
15. Rivaroxaban 23%
16. Meta-Analysis 21%
17. Point-of-Care Systems 21%
18. Thrombin 20%
19. Coronavirus 19%
20. Stroke 19%
21. vorapaxar 18%
22. apixaban 18%
23. Aspirin 18%
24. Platelet Aggregation Inhibitors 17%
25. Systematic Reviews 17%
26. Cardiovascular Diseases 17%
27. Reperfusion 17%
28. Biomarkers 15%
29. Out-of-Hospital Cardiac Arrest 14%
30. Cardiology 14%
31. Coronary Vessels 14%
32. Mortality 14%
33. Dabigatran 13%
34. Heart 13%
35. Morphine 12%
36. Stents 12%
37. Venous Thromboembolism 12%
38. Prasugrel Hydrochloride 12%
39. Warfarin 11%
40. Drug-Eluting Stents 11%
41. Clopidogrel 11%
42. Non-ST Elevated Myocardial Infarction 11%
43. Equipment and Supplies 10%
44. Randomized Controlled Trials 10%
45. Safety 10%
46. Fibrin 10%
47. Coronary Disease 10%
48. Thrombophilia 9%
49. Survival 9%
50. Coronary Thrombosis 9%